Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Historical Holders from Q4 2015 to Q3 2025

Symbol
KURA on Nasdaq
CUSIP
50127T109
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
87M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
83.9M
Holdings value
$742M
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
197
Number of buys
118
Number of sells
-71
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 9.99% +31.1% $76.8M $24.5M 8.68M +46.8% BVF PARTNERS L P/IL Sep 30, 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% +38.6% $45.1M $14.1M 7.56M +45.5% SUVRETTA CAPITAL MANAGEMENT, LLC Mar 31, 2025
BlackRock, Inc. 7.8% -24% $37.8M -$9.58M 6.33M -20.2% BlackRock, Inc. Mar 31, 2025
ARMISTICE CAPITAL, LLC 5.37% -27.8% $41.3M -$16.8M 4.67M -28.9% Armistice Capital, LLC Sep 30, 2025
EcoR1 Capital, LLC 4.8% $25.3M 4.2M EcoR1 Capital, LLC Jun 30, 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% $23.9M 4M RA Capital Management, L.P. Mar 31, 2025

Institutional Holders of Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 83.9M $742M +$27.2M $8.85 197
2025 Q2 82.2M $474M +$3.89M $5.77 180
2025 Q1 80.5M $531M -$1.74M $6.60 183
2024 Q4 78.8M $686M -$218M $8.71 184
2024 Q3 82.4M $1.61B +$3.96M $19.54 178
2024 Q2 80.5M $1.66B -$4.36M $20.59 173
2024 Q1 80.7M $1.72B +$49.5M $21.33 163
2023 Q4 40.2K $577K -$446K $14.35 2
2023 Q3 75.2M $685M -$2.89M $9.12 129
2023 Q2 75.1M $795M +$20.1M $10.58 146
2023 Q1 72.4M $885M +$27.5M $12.23 139
2022 Q4 70.1M $870M -$24.8M $12.41 137
2022 Q3 71.5M $977M -$9.87M $13.66 139
2022 Q2 68.6M $1.26B +$54.2M $18.33 140
2022 Q1 64.7M $1.04B +$41.7M $16.08 137
2021 Q4 62M $869M -$106M $14.00 137
2021 Q3 65.7M $1.23B -$23.4M $18.73 147
2021 Q2 66.6M $1.39B -$37.9M $20.85 162
2021 Q1 68.5M $1.94B +$125M $28.27 160
2020 Q4 62.5M $2.04B +$339M $32.66 184
2020 Q3 53.1M $1.63B +$43.2M $30.64 157
2020 Q2 52.2M $851M +$209M $16.30 125
2020 Q1 39.6M $393M +$5.32M $9.95 111
2019 Q4 38.8M $533M -$12.8M $13.75 123
2019 Q3 39.2M $595M +$25.3M $15.17 111
2019 Q2 37.3M $734M +$138M $19.69 119
2019 Q1 30.4M $504M +$1.16M $16.59 96
2018 Q4 30.5M $428M -$2.84M $14.04 92
2018 Q3 30.1M $527M +$9.42M $17.50 109
2018 Q2 29.7M $538M +$109M $18.20 107
2018 Q1 23.5M $440M +$77.1M $18.75 96
2017 Q4 18M $275M -$7.19M $15.30 71
2017 Q3 19.2M $287M +$127M $14.95 63
2017 Q2 10.8M $101M +$4.77M $9.30 42
2017 Q1 10.3M $90.7M +$4.18M $8.80 34
2016 Q4 9.88M $58.2M +$735K $5.90 29
2016 Q3 9.75M $60.9M +$2.8M $6.25 26
2016 Q2 9.32M $25.2M -$2.97M $2.71 25
2016 Q1 10.2M $40.7M -$957K $4.05 19
2015 Q4 10.2M $86.1M +$80.3M $8.40 14